PharmAla Biotech Swaps Auditors, Expands Investor Relations Outreach
Event summary
- PharmAla Biotech replaced its auditor, Clearhouse LLP, with Davidson & Company LLP to meet U.S. PCAOB mandate requirements.
- The company signed a $58,000 annual agreement with Water Tower Research for investor engagement and research services.
- PharmAla engaged Oak Hill Financial for capital markets advisory services at a $12,000 monthly fee.
The big picture
PharmAla Biotech’s auditor change reflects a strategic pivot toward U.S. regulatory compliance, while its investments in investor relations signal a push to broaden its institutional appeal. The moves come as the psychedelics sector faces increasing scrutiny over governance and transparency, making PharmAla’s governance shifts a key indicator of broader industry trends.
What we're watching
- Auditor Transition
- How the switch to a PCAOB-compliant auditor will impact PharmAla’s reporting timelines and costs.
- Investor Relations Strategy
- Whether the $58,000 annual investment in Water Tower Research will translate into measurable investor engagement.
- Capital Markets Momentum
- The pace at which Oak Hill Financial can elevate PharmAla’s profile among institutional investors.
Related topics